Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:51:02.994Z.
Calculation as of: 2026-10-06T12:51:02.994Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-09-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$637.59M
Price/FCF Ratio
N/A
TTM Avg
59.55
3Y Avg
26.45
5Y Avg
31.22
Market Cap
$642.31M
Price/FCF Ratio
1264.38
TTM Avg
742.47
3Y Avg
742.47
5Y Avg
415.90
Market Cap
$596.36M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$675.41M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$579.88M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$573.38M
Price/FCF Ratio
N/A
TTM Avg
16.85
3Y Avg
16.85
5Y Avg
16.85
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $632.76M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | N/A | 59.55 | 26.45 | 31.22 |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | 1264.38 | 742.47 | 742.47 | 415.90 |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $688.14M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 16.85 | 16.85 | 16.85 |
| CorMedix Inc. (CRMD)vs › | $569.56M | 2.28 | 8.28 | 11.19 | 11.19 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2024-09-30 | 2710.16 |
| 2024-09-27 | 2651.59 |
| 2024-09-26 | 2662.24 |
| 2024-09-25 | 2928.47 |
| 2024-09-24 | 3492.86 |
| 2024-09-23 | 4062.58 |
| 2024-09-20 | 4488.54 |
| 2024-09-19 | 4408.67 |
| 2024-09-18 | 4248.94 |
| 2024-09-17 | 4238.29 |
| 2024-09-16 | 4387.38 |
| 2024-09-13 | 4504.51 |
| 2024-09-12 | 4259.59 |
| 2024-09-11 | 4190.37 |
| 2024-09-10 | 4163.75 |
| 2024-09-09 | 4169.07 |
